We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antihypertensive therapy, the α-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
- Authors
Davis, B. R.; Arnett, D. K.; Boerwinkle, E.; Ford, C. E.; Leiendecker-Foster, C.; Miller, M. B.; Black, H.; Eckfeldt, J. H.
- Abstract
In a double-blind, outcome trial conducted in hypertensive patients randomized to chlorthalidone (C), amlodipine (A), lisinopril (L), or doxazosin (D), the α-adducin Gly460Trp polymorphism was typed (n=36 913). Mean follow-up was 4.9 years. Relative risks (RRs) of chlorthalidone versus other treatments were compared between genotypes (Gly/Gly+Gly/Trp versus Trp/Trp). Primary outcome was coronary heart disease (CHD). Coronary heart disease incidence did not differ among treatments or genotypes nor was there any interaction between treatment and genotype (P=0.660). Subgroup analyses indicated that Trp allele carriers had greater CHD risk with C versus A+L in women (RR=1.31) but not men (RR=0.91) with no RR gender differences for non-carriers (gender–gene–treatment interaction, P=0.002). The α-adducin gene is not an important modifier of antihypertensive treatment on cardiovascular risk, but women Trp allele carriers may have increased CHD risk if treated with C versus A or L. This must be confirmed to have implications for hypertension treatment.The Pharmacogenomics Journal (2007) 7, 112–122. doi:10.1038/sj.tpj.6500395; published online 16 May 2006
- Subjects
HYPERTENSION; THERAPEUTICS; ANTIHYPERTENSIVE agents; CARDIOVASCULAR diseases; PATIENTS; AMLODIPINE; CLINICAL trials; PHARMACOGENOMICS; GENETICS
- Publication
Pharmacogenomics Journal, 2007, Vol 7, Issue 2, p112
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/sj.tpj.6500395